NAS:AVXL (USA) Also trade in: Germany UK

Anavex Life Sciences Corp

$ 2.54 -0.28 (-9.93%)
Volume: 1,147,764 Avg Vol (1m): 528,040
Market Cap $: 128.86 Mil Enterprise Value $: 109.40 Mil
P/E (TTM): 0.00 P/B: 8.45
Earnings Power Value 0.5
Net Current Asset Value 0.3
Tangible Book 0.3
Projected FCF -1.33
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7.1/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 0, Med: 1, Max: 10000
Current: 10000
0
10000
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.58
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 13.6%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -122.42
ROE range over the past 10 years
Min: -186.25, Med: -121.13, Max: -78.01
Current: -122.42
-186.25
-78.01
ROA % -100.17
ROA range over the past 10 years
Min: -7687.04, Med: -1040, Max: -66.85
Current: -100.17
-7687.04
-66.85
3-Year Total EBITDA Growth Rate -16.80
3-Year EBITDA Growth Rate range over the past 10 years
Min: -472.3, Med: -2.8, Max: 32.4
Current: 12.8
-472.3
32.4
3-Year EPS w/o NRI Growth Rate 15.70
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0.9, Max: 33.6
Current: 15.7
0
33.6

» AVXL's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AVXL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 8731
Compare NAS:HOOK SZSE:002604 XKRX:203690 NAS:BTAI OSTO:NUE NAS:SBBP XPAR:COX NAS:SLGL LSE:ERGO NAS:ARDX ROCO:6589 NAS:EYPT TSE:2385 NAS:DYAI NAS:ENOB XKRX:064550 ROCO:6575 XBRU:OXUR OCSE:ORPHA ROCO:4743
Traded in other countries 12X1.Germany 0HFR.UK
Address 51 West 52nd Street, 7th Floor, New York, NY, USA, 10019
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States. It is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer's disease, other central nervous systems (CNS) diseases, pain and several types of cancer. The lead compound of the company is ANAVEX 2-73 which is developed to treat Alzheimer's disease, Parkinson's disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. The research and development pipeline of the company includes one clinical drug candidate and several compounds in various stages of the pre-clinical study.

Ratios

Current vs industry vs history
PB Ratio 8.45
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 47.74
Current: 8.45
0
47.74
EV-to-EBIT -4.22
EV-to-EBIT range over the past 10 years
Min: -17.59, Med: 0, Max: 6.07
Current: -4.22
-17.59
6.07
EV-to-EBITDA -4.22
EV-to-EBITDA range over the past 10 years
Min: -17.59, Med: 0, Max: 6.07
Current: -4.22
-17.59
6.07
Current Ratio 3.23
Current Ratio range over the past 10 years
Min: 0.01, Med: 0.67, Max: 17.08
Current: 3.23
0.01
17.08
Quick Ratio 3.23
Quick Ratio range over the past 10 years
Min: 0.01, Med: 0.67, Max: 17.08
Current: 3.23
0.01
17.08

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.10
3-Year Share Buyback Rate range over the past 10 years
Min: -58.5, Med: -15.85, Max: -2.6
Current: -15.1
-58.5
-2.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 8.47
Price-to-Tangible-Book range over the past 10 years
Min: 1.81, Med: 8.18, Max: 46.25
Current: 8.47
1.81
46.25
Earnings Yield (Joel Greenblatt) % -23.60
Earnings Yield (Greenblatt) range over the past 10 years
Min: -5000, Med: 0, Max: 10434.8
Current: -23.6
-5000
10434.8

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N